Search Results for “Roche” – Page 7 – media

Roche’s Erivedge no longer funded by the NHS

Roche’s Erivedge will indeed no longer be funded on the National Health Service(NHS) as a treatment for skin cancer after cost regulators issued final guidance ruling that it is not cost effective.
- Source: news.open-medical
- 549
- November 27, 2017
BCC Company Insight Erivedge NHS Roche skin cancer
US FDA grants Breakthrough Therapy Designation for Roche’s Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC

The latest BTD was granted for the treatment of adult patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor.
- Source: Roche
- 560
- November 23, 2017
anaplastic lymphoma kinase Company Insight FDA non-small cell lung cancer Roche
Roche secures FDA approval for Zika virus screening test

Roche has secured approval from the US Food and Drug Administration (FDA) for its cobas Zika test to detect RNA of the Zika virus in human plasma samples.
- Source: medicaldevice-network
- 680
- October 11, 2017
FDA New Approvals plasma Zika
EU green light for Roche’s Tecentriq

Roche has received European Commission(EC) approval for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab) to treat specific lung and bladder cancers. The green light means that it can be used as monotherapy for people in the EU with previously-treated locally advanced or metastatic non-small cell cancer (NSCLC), or those with metastatic urothelial carcinoma (mUC) who have received a platinum-based chemotherapy or who are ineligible to receive cisplatin chemotherapy.
- Source: Pharmatimes
- 564
- September 26, 2017
bladder cancer Company Insight immunotherapy lung
Roche out-licneses lebrikizumab to Dermira

Roche has agreed to out-license certain rights to its invesitgational atropic dermatitis drug lebrikizumab to Demira in a deal that could be worth more than $1.4 billion.
- Source: pharmatimes
- 446
- August 10, 2017
Company Insight dermatitis Dermira lebrikizumab Market Views
Roche reports strong performance in the first half of 2017

Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful launch of Ocrevus for the treatment of two forms of multiple sclerosis. Based on our half-year performance, we raised the outlook for the full-year to mid-single digit sales growth.”
- Source: www.roche.com
- 512
- August 4, 2017
Company Insight
Regeneron’s midlife crisis

Regeneron is a role model for the biotech community. No biotech company wants to be Regeneron. “Becoming China’s Regeneron” is the slogan of many domestic biotechs. However, such a Regeneron cannot escape its midlife crisis. The attack of opponents, the victory of Eylea generic drugs, and the successive blows of dual-antibodies have put Regeneron in an extremely delicate stage. On the one hand, with two blockbuster drugs, Regeneron has completed the transformation from biotech to big pharma. In the first half of the year, its stock price continued to rise, successfully breaking through the $100 billion threshold, and its market value reached $133.2 billion. On the other hand, although the market believes in Regeneron’s R&D and platform technology capabilities, how can a new billion-dollar blockbuster drug be so easy? And Regeneron’s highly anticipated oncology business is not as glamorous as autoimmunity and ophthalmology, and its progress is also lackluster. So ...
- Source: drugdu
- 43
- November 22, 2024
Johnson&Johnson Medical Technology, organizational restructuring

Recently, Johnson&Johnson Medical Technology has made organizational adjustments to its surgical division. Starting from January 1, 2025, the Surgery Division will be reorganized into six major departments: Minimally Invasive and Energy Surgery Division, Wound Closure Division, Biosurgery Division, Surgical Product Expansion Division (i.e. Wide Area Market Division), Strategic Marketing Division, and Robotics and Digitalization Division. 01. Adjustment of the Organizational Structure of the Surgical Division Given the rapid changes in policy environment and the new trend of market competition, Johnson&Johnson Medical Technology firmly believes that the Surgical Division’s continued leadership in the market in the new era is an important cornerstone for winning the Chinese market and the future. To this end, the company has launched the “Yaoying 2030” surgical division strategy, aiming to accelerate the transformation of the GTM model and cover more customers and patients with better and faster services. In the new stage of development, Johnson&Johnson Medical ...
- Source: drugdu
- 65
- November 15, 2024
Analytica Vietnam

Organiser：Messe München GmbH (Munich Exhibition Center) Time：April 2nd – 4th, 2025 Address：Plot No. 23 – 25 & 27 – 29, Knowledge Park – II, Gautam Budh Nagar, Greater NOIDA – 201306 Exhibition hall：Saigon Exhibition and Convention Center (SECC) Product range: Medical Products: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, emergency rescue equipment, diagnostic equipment and supplies, ophthalmic instruments and equipment, ENT equipment, dental equipment and supplies, medical reagents and equipment, medical healthcare products and equipment, medical institution and laboratory technology equipment, medical information and technology exchange, beauty instruments. Analytical Instruments: Optical analytical instruments, mass spectrometers, spectroscopes, chromatographs, spectrographs, spectrometers, electrochemical analytical instruments, ray analytical instruments, gas chromatographs, liquid chromatographs, thermal analytical instruments, various portable instruments, surface analytical instruments, nuclear analytical instruments, elemental analytical instruments, process analytical instruments, compositional analytical instruments, injection analytical instruments, and other general analytical instruments. Laboratory Equipment: Laboratory instruments and equipment, laboratory automation ...
- Source: drugdu
- 72
- November 7, 2024
$1.4 billion deal highlights the future of Alzheimer’s disease therapy

The development of therapies for Alzheimer’s disease has always caused many developers to feel exhausted, and now AbbVie has also increased its investment in neurodegenerative diseases. AbbVie has agreed to spend $1.4 billion to acquire Aliada Therapeutics, whose main acquisition asset is Aliada’s authorized Alzheimer’s disease candidate drug ALIA-1758 from Johnson&Johnson. Its mechanism of action is still an anti beta amyloid protein (3pE-A β) antibody, but the unique feature of ALIA-1758 is that it can cross the blood-brain barrier, greatly improving the brain’s absorption rate. Aliada started a phase 1 trial among healthy volunteers in May, but AbbVie believes the timing is ripe for acquisition. Previously, AbbVie made the decision to abandon its internal Alzheimer’s disease asset ABBV-916. This anti beta amyloid antibody has no significant difference in safety and efficacy compared to the already marketed monoclonal antibody therapy for Alzheimer’s disease. Therefore, AbbVie decided to terminate the development ...
- Source: drugdu
- 59
- November 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.